To assess whether the hyperglycemia that we observed in Batf3-/- mice contributes to the impaired intestinal barrier and subsequent pro-inflammatory phenotype in Batf3-/- mice, we treated 16-week-old WT and Batf3-/- mice with 2-DG, an inhibitor of glucose metabolism, for 10 days (Figure 7A). The gene discussed is BATF3; the disease is Hyperglycemia.